Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $193000.0.

  • Cytosorbents' Change in Accured Expenses rose 11701.94% to $193000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 14571.27%. This contributed to the annual value of -$1.8 million for FY2024, which is 21245.57% down from last year.
  • Per Cytosorbents' latest filing, its Change in Accured Expenses stood at $193000.0 for Q3 2025, which was up 11701.94% from $7282.0 recorded in Q2 2025.
  • Cytosorbents' Change in Accured Expenses' 5-year high stood at $2.1 million during Q4 2021, with a 5-year trough of -$1.3 million in Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$206441.0 (2022), whereas its average is -$62598.8.
  • In the last 5 years, Cytosorbents' Change in Accured Expenses crashed by 49089.85% in 2022 and then skyrocketed by 37110.22% in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Change in Accured Expenses stood at $2.1 million in 2021, then tumbled by 109.71% to -$206441.0 in 2022, then surged by 371.1% to $559666.0 in 2023, then soared by 142.72% to $1.4 million in 2024, then crashed by 85.79% to $193000.0 in 2025.
  • Its last three reported values are $193000.0 in Q3 2025, $7282.0 for Q2 2025, and -$367282.0 during Q1 2025.